Does kojic acid work for hyperpigmentation?

How strong is the evidence?

Bottom line: kojic acid has a moderate evidence base for melasma, not a strong one. A systematic review graded it as a recommendation for melasma, alongside hydroquinone, triple combination creams, sunscreens, and azelaic acid (systematic review of melasma therapies).

A meta-analysis of 45 studies and 2,359 patients found kojic acid's effect comparable to the other agents it was measured against, with a standardized mean difference of -0.9 (meta-analysis of topical melasma agents). Pooled numbers are useful, but they flatten differences in trial design and do not translate neatly into what you will see in the mirror.

The catch is trial size. An evidence review found only four randomized trials on kojic acid in melasma, with small samples and strengths ranging from 0.75% to 2% (evidence-based review and grading for melasma).

How does it compare with hydroquinone?

Bottom line: hydroquinone is still the benchmark, and kojic acid usually looks slower. In one comparison against 4% hydroquinone, a kojic acid product (0.75% with 2.5% vitamin C) was inferior, and hydroquinone improved melasma faster and by a significantly larger margin (evidence-based review).

The picture shifts at matched strength. In a split-face trial of 39 patients, 2% kojic acid and 2% hydroquinone showed no difference, though both sides also received 5% glycolic acid, which muddies the result (evidence-based review).

Combinations performed best in these small trials. In a single-blind trial, 1% kojic acid alone improved MASI by 58.72%, while kojic acid plus 2% hydroquinone reached 71.87% (evidence-based review). That three-month study found the combination group had the highest efficacy (comparative trial).

A recent open-label trial of 72 Indian women found 2% kojic acid nightly for 16 weeks reduced mMASI by 10%, versus 12.25% with 5% cysteamine. The gap was not statistically significant, and 13 of 34 kojic acid patients (38%) reported improvement. Open-label design means nobody was blinded, so treat it cautiously (cysteamine versus kojic acid trial).

A small Thai split-face pilot compared 2% kojic acid with 5% alpha-arbutin against a triple combination cream. It is too preliminary to lean on, so we would not read much into it yet (split-face pilot).

What are the side effects?

Bottom line: irritation is less common with kojic acid than with hydroquinone-based combinations, but contact allergy is the risk to watch. Pooled irritation was 5.3% for kojic acid, versus 50.9% for hydroquinone-containing combinations and 42.2% for cysteamine. These trials differ widely, so cross-agent comparisons are rough (meta-analysis of topical melasma agents).

The most concrete sensitization data come from a 1992–93 patch-test study of 220 women with suspected cosmetic dermatitis. Five of the eight who had used kojic acid products reacted to it, and none of the 212 who had not used them reacted. Reactions appeared one to 12 months after starting use. The exposed group was tiny and these patients were already referred for testing, so the study signals risk without measuring it well (patch-test study).

Concentration matters. Marketed products typically contain 0.2–1%. Some reports advise staying at or below 1% to limit irritation, while others consider up to 2% safe (kojic acid review). Kojic acid is also less stable than hydroquinone and degrades with light, heat, and oxidation (nanocapsule study).

Hydroquinone carries a known risk of exogenous ochronosis, a hard-to-reverse blue-black discoloration. The review treats kojic acid as the safer option, but that rests on comparative reasoning rather than head-to-head safety trials (kojic acid review).

What we don't know yet

Bottom line: the evidence is real but thin, and several gaps matter for your decision. Kojic acid inhibits tyrosinase, the enzyme that drives melanin production, and it has antioxidant activity (quasi-drug review from Japan). That mechanism is plausible, but it is not the same as clinical proof.

• Most trials enrolled roughly 12 to 72 patients and ran 12 to 16 weeks.
• Many were open-label or single-blind, and few used standardized concentrations or long follow-up.
• No head-to-head trials compare 1% with 2% kojic acid, so the dose-response is unclear.
• We found no pregnancy, lactation, or multi-year safety data.
• We found no AAD, FDA, or other regulator guidance on kojic acid for hyperpigmentation, and we did not verify its US regulatory status.

Evidence specific to post-inflammatory hyperpigmentation is also thin. A laser review lists kojic acid as a possible option for PIH, but that was not tested in kojic acid-specific trials (laser and topical review). A 12-patient uncontrolled study using 3% kojic acid reported brighter skin in 75% of participants, which is hypothesis-generating at best (hyperspectral imaging study).

A sensible way to try it

Bottom line: if you want to try kojic acid, consider a product at the lower end of the marketed range (typically 0.2–1%), and use daily sunscreen. Reactions can appear months after starting, so stop use if irritation develops. For more on the ingredient itself, see our kojic acid explainer. If you have melasma that is not responding, a dermatologist can discuss options with better evidence behind them.